Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Iron Deficiency Anemia Therapy Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_
The iron deficiency anemia therapy market size has demonstrated significant expansion in recent years. It is forecast to grow from $4.78 billion in 2025 to $5.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The historic period’s growth drivers include the increasing prevalence of iron deficiency anemia, rising awareness of anemia management, expansion of hospital-based treatment protocols, growing use of oral iron supplements, and improved diagnostic screening for anemia._x000D_
_x000D_
The iron deficiency anemia therapy market size is anticipated to experience substantial expansion over the upcoming years. It is projected to reach $6.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This projected growth during the forecast period can be linked to factors such as the increasing need for quicker anemia correction, the growing occurrence of chronic illnesses that lead to anemia, the proliferation of specialized anemia clinics, a heightened focus on maternal and pediatric anemia care, and improvements in iron formulation technologies. Key developments expected during this period involve a rise in the adoption of intravenous iron therapies, an increasing demand for targeted anemia treatments, a greater emphasis on personalized patient therapy regimens, the development of combined oral and parenteral therapies, and an enhanced focus on ensuring treatment effectiveness and safety._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Iron Deficiency Anemia Therapy Market Industry Drivers: What’s Behind The Revenue Growth?#_x000D_
The iron deficiency anemia therapy market is projected to expand due to the escalating number of chronic disease cases. Chronic diseases are long-term medical conditions typically persisting for at least a year. The rise in these conditions is linked to an increased prevalence of unhealthy lifestyle choices, including poor diet, lack of physical activity, and smoking, which contribute to ailments such as obesity, diabetes, and heart disease, leading to lasting health complications. Chronic conditions can heighten the demand for iron deficiency anemia therapy by impairing the body’s ability to absorb iron effectively, thereby increasing the risk of iron deficiency and necessitating supplementation or treatment to restore iron levels. For instance, in June 2024, the National Health Service, a UK-based government department, reported that 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023. This marked an 18% increase from 3,065,825 cases recorded in 2022. Thus, the increasing incidence of chronic diseases is propelling growth within the iron deficiency anemia therapy market._x000D_
_x000D_
#Iron Deficiency Anemia Therapy Market Segment Breakdown: Which Categories Lead On Revenue?#_x000D_
The iron deficiency anemia therapy market covered in this report is segmented – _x000D_
_x000D_
1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide_x000D_
2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types_x000D_
3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology _x000D_
4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies_x000D_
5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations_x000D_
2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations_x000D_
3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups_x000D_
4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations_x000D_
_x000D_
#Iron Deficiency Anemia Therapy Market Growth Trends: What’s Shaping The Future Outlook?_x000D_
Major companies within the iron deficiency anemia therapy market are concentrating on creating improved treatment alternatives, such as injectable formulations, to enhance both treatment effectiveness and ease of access. An injectable formulation refers to a recently developed or modified drug version administered via injection. For example, in May 2023, Emcure Pharmaceuticals Ltd., an Indian pharmaceutical firm, introduced Orofer FCM 750, a ferric carboxymaltose (FCM) formulation designed for treating iron deficiency and iron deficiency anemia (IDA). This product offers advantages like enhanced patient adherence due to less frequent dosing compared to oral supplements. Its primary goal is to effectively manage iron deficiency anemia, particularly in individuals unable to tolerate oral iron supplements. This 750 mg/15 ml injectable ferric carboxymaltose received approval from India’s DCGI for iron deficiency anemia (IDA) in patients who do not respond to oral iron, especially pregnant women with hemoglobin <10 g/dl and weighing 35–70 kg, providing a 15-minute infusion (when diluted in saline) and adhering to Anemia Mukt Bharat guidelines as a preferred initial treatment for severe conditions._x000D_
_x000D_
#Iron Deficiency Anemia Therapy Market Competitive Landscape: Which Companies Lead The Industry?#_x000D_
Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc, Abbott Laboratories, Bayer AG, Pfizer Inc., Lupin Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd. _x000D_
_x000D_
#View The Full Iron Deficiency Anemia Therapy Market Report:#_x000D_
_x000D_
#Iron Deficiency Anemia Therapy Market Regional Outlook: Where Is Opportunity Concentrated?#_x000D_
North America was the largest region in the iron deficiency anemia therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
